Extracorporeal immunoadsorption treatment for rheumatoid arthritis
Hailey D, Topfer L A
Record ID 32002000367
English, French
Authors' objectives:
To summarise the available evidence on extracorporeal immunoadsorption treatment for rheumatoid arthritis.
Authors' recommendations:
- Immunoadsorption treatment is a non-drug therapy for rheumatoid arthritis. The treatment is based on filtering the patient's plasma through a column containing staphylococcal protein A.
- The treatment is effective in alleviating the symptoms of severe rheumatoid arthritis in some patients. Data on long-term outcomes are not available.
- The mechanism of action of this treatment is unclear.
- Most adverse effects are associated with the apheresis procedure.
- The cost per 12 week course of treatment is likely to be more than 20,000 Canadian dollars. The cost-effectiveness of the technology is not yet established.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/research/index.html
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Arthritis, Rheumatoid
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.